Dexcom announced this week that it will deploy an advanced artificial intelligence upgrade to its Stelo over-the-counter glucose biosensor app in all 50 states within the next four weeks. The new module leverages a proprietary nutrition database of more than one million food items, delivering detailed breakdowns of calories, carbohydrates, protein, fat and dietary fiber for every logged meal. Users can capture meals via text search, barcode scan or photo recognition, and the system automatically syncs nutrient data to their glucose curves. In a real-world study of over 2,000 Stelo users conducted in late 2025, 78% reported more consistent meal logging and a 22% reduction in post-prandial glucose variability after one month of use. Girish Naganathan, DXCM’s chief technology officer, said the update ‘‘eliminates nutrition-tracking friction so users can make health-conscious decisions with greater confidence.”

Analysts covering DXCM raised their 2026 consensus earnings estimate by 5% over the past six weeks, driven by robust Stelo subscription growth and accelerating sensor sales in Europe. Thirteen of 16 analysts now expect Dexcom to report year-over-year revenue growth north of 20% for the quarter ending March, with adjusted EPS forecast to climb by 18%. Institutional ownership stands at 72%, up from 68% three months ago, signaling increased conviction among large managers. Market research firm MedTech Insights projects Dexcom will ship 1.4 million continuous glucose monitoring sensors in Q1, a 25% increase over the same period last year. Investors will be watching the company’s forward-looking guidance closely, as management is poised to update its full-year sensor placement and Stelo subscription targets during the upcoming earnings call.